1. Home
  2. CCO vs CAPR Comparison

CCO vs CAPR Comparison

Compare CCO & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CCO
  • CAPR
  • Stock Information
  • Founded
  • CCO 1995
  • CAPR 2005
  • Country
  • CCO United States
  • CAPR United States
  • Employees
  • CCO N/A
  • CAPR N/A
  • Industry
  • CCO Advertising
  • CAPR Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • CCO Consumer Discretionary
  • CAPR Health Care
  • Exchange
  • CCO Nasdaq
  • CAPR Nasdaq
  • Market Cap
  • CCO 472.0M
  • CAPR 392.8M
  • IPO Year
  • CCO 2005
  • CAPR N/A
  • Fundamental
  • Price
  • CCO $0.96
  • CAPR $11.25
  • Analyst Decision
  • CCO Buy
  • CAPR Strong Buy
  • Analyst Count
  • CCO 3
  • CAPR 7
  • Target Price
  • CCO $2.05
  • CAPR $39.29
  • AVG Volume (30 Days)
  • CCO 2.7M
  • CAPR 1.4M
  • Earning Date
  • CCO 05-01-2025
  • CAPR 05-12-2025
  • Dividend Yield
  • CCO N/A
  • CAPR N/A
  • EPS Growth
  • CCO N/A
  • CAPR N/A
  • EPS
  • CCO N/A
  • CAPR N/A
  • Revenue
  • CCO $1,505,230,000.00
  • CAPR $22,270,465.00
  • Revenue This Year
  • CCO $6.83
  • CAPR $78.85
  • Revenue Next Year
  • CCO $3.73
  • CAPR $157.99
  • P/E Ratio
  • CCO N/A
  • CAPR N/A
  • Revenue Growth
  • CCO 4.95
  • CAPR N/A
  • 52 Week Low
  • CCO $0.81
  • CAPR $3.52
  • 52 Week High
  • CCO $1.88
  • CAPR $23.40
  • Technical
  • Relative Strength Index (RSI)
  • CCO 39.42
  • CAPR 52.49
  • Support Level
  • CCO $0.89
  • CAPR $9.43
  • Resistance Level
  • CCO $1.04
  • CAPR $10.09
  • Average True Range (ATR)
  • CCO 0.10
  • CAPR 0.93
  • MACD
  • CCO 0.00
  • CAPR 0.22
  • Stochastic Oscillator
  • CCO 44.12
  • CAPR 97.82

About CCO Clear Channel Outdoor Holdings Inc.

Clear Channel Outdoor Holdings Inc is a provider of out-of-home advertising solutions. The company offers advertisers an opportunity to reach mass audiences across various high-traffic public spaces, by using its diverse portfolio of assets including roadside billboards, street furniture, and airport displays. Its reportable segments are; America (U.S. operations excluding airports), Airports (U.S. and Caribbean airport operations), and Other. A majority of its revenue is generated from the America segment which generates revenue from the sale of advertising on printed and digital out-of-home advertising displays such as bulletins, posters, street furniture, and others. Geographically, the company generates maximum revenue from the United States followed by Singapore.

About CAPR Capricor Therapeutics Inc.

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

Share on Social Networks: